Alzheimer's Disease Diagnostic Market Report 2026

The alzheimer’s disease diagnostic market size has grown rapidly in recent years. It will grow from $7.26 billion in 2025 to $8.03 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to rising prevalence of alzheimer’s disease, increased awareness of neurodegenerative disorders, adoption of mri and pet imaging, growth of diagnostic centers and hospitals, investment in cognitive assessment research.

The alzheimer’s disease diagnostic market size is expected to see rapid growth in the next few years. It will grow to $11.89 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to development of novel biomarkers and imaging tracers, integration of ai for early diagnosis, rising government and private funding for alzheimer’s research, expansion of personalized medicine initiatives, growth in multi-center clinical trials. Major trends in the forecast period include increasing adoption of biomarker-based diagnostics, rising use of neuroimaging techniques for early detection, growth in cognitive assessment testing, expansion of genetic testing for alzheimer’s risk assessment, integration of multi-modal diagnostic approaches.

The rising prevalence of chronic disease is expected to drive the growth of the Alzheimer’s disease diagnostic market in the coming years. Chronic conditions such as cardiovascular disease, diabetes, and hypertension are strongly linked to an increased risk of Alzheimer’s and other dementias, which fuels demand for early and accurate diagnostic solutions. A key factor contributing to the rise in chronic diseases is the widespread adoption of sedentary lifestyles, as extensive epidemiological research consistently shows significantly higher rates of conditions like diabetes and cardiovascular disease among physically inactive populations. Alzheimer’s diagnostics support healthcare systems by enabling early detection, facilitating timely interventions, and guiding patient management to slow disease progression. For instance, in November 2023, according to Heritage Health Services, a US-based nonprofit organization focused on healthcare research, 6.7 million Americans aged 65 or older were living with Alzheimer’s dementia, with prevalence increasing by age: 5% for 65-74 years, 13.1% for 75-84 years, and 33.3% for 85+ years. By 2050, this number is projected to reach nearly 13 million. Therefore, the rising prevalence of chronic disease is fueling the growth of the Alzheimer’s disease diagnostic market.

Major companies in the Alzheimer’s disease diagnostic market are focusing on the development of blood-based biomarker tests, which are expected to simplify the diagnostic process for Alzheimer’s disease, reduce reliance on more invasive procedures, and improve patient access to timely treatment. For instance, in October 2023, Quanterix, a US-based biotechnology research company, launched the LucentAD p-Tau 217 test, a blood-based biomarker for Alzheimer’s pathology with high clinical sensitivity and specificity. Traditional diagnostic methods for cerebrospinal fluid (CSF) biomarkers often involve positron emission tomography (PET) or lumbar puncture, both of which are costly, invasive, and not widely accessible. The test combines Quanterix’s ultra-sensitive Simoa® technology with J&J Innovative Medicine’s well-validated p-Tau 217 antibodies, offering excellent accuracy and a simplified process.

In July 2024, Lantheus, a US-based radiopharmaceutical company, acquired Meilleur Technologies for an undisclosed sum. Through this acquisition, Lantheus aims to expand its portfolio of PET imaging agents for Alzheimer’s disease. Meilleur Technologies is a US-based biopharmaceutical company that collaborates with research institutions to develop imaging biomarkers for Alzheimer’s disease.

Major companies operating in the alzheimer’s disease diagnostic market are Hoffmann-La Roche, Eli Lilly and Company, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Lantheus, Quanterix, C2N Diagnostics, Sysmex, Royal Philips, Bruker Corporation, Revvity, Alamar Biosciences, ADx Neurosciences, Randox Laboratories, DiaSorin, Shenzhen Mindray Bio-Medical Electronics, Nipro Corporation, Canon Inc, Hitachi Ltd, Eisai Co Ltd.

North America was the largest region in the alzheimer's disease diagnostic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the alzheimer’s disease diagnostic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the alzheimer’s disease diagnostic market by increasing costs for imported imaging equipment, biomarker reagents, and genetic testing kits. Segments such as imaging techniques and biomarker testing are most affected, with regions including north america, europe, and asia-pacific facing higher procurement costs. These tariffs have led to increased operational expenses for diagnostic centers and hospitals. On the positive side, tariffs have encouraged local manufacturing of diagnostic tools and reagents and spurred innovation in domestic production capabilities.

The alzheimer’s disease diagnostic market research report is one of a series of new reports that provides alzheimer’s disease diagnostic market statistics, including alzheimer’s disease diagnostic industry global market size, regional shares, competitors with a alzheimer’s disease diagnostic market share, detailed alzheimer’s disease diagnostic market segments, market trends and opportunities, and any further data you may need to thrive in the alzheimer’s disease diagnostic industry. This alzheimer’s disease diagnostic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Alzheimer’s disease diagnostics involve the methods and tools used to detect and confirm the presence of Alzheimer’s disease, a progressive neurodegenerative disorder. These diagnostics include cognitive assessments, imaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, and biomarker tests that analyze cerebrospinal fluid (CSF) or blood for amyloid-beta and tau proteins.

The main types of Alzheimer’s disease diagnostics are triage, diagnosis, and screening. Triage is a structured approach for prioritizing patients based on the urgency and severity of their cognitive symptoms. Diagnostic techniques include biomarkers, imaging methods, genetic testing, and cognitive assessment tests, and they are utilized by end-users such as clinics, hospitals, diagnostic centers, pharmaceutical companies, and academic research institutions.

The alzheimer's disease diagnostic market consists of revenues earned by entities by providing services such as cognitive assessment tests, genetic tests, biomarker tests, and cerebrospinal fluid analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The alzheimer's disease diagnostic market also includes sales of genetic testing kits, cognitive assessment tools, imaging equipment, biomarker kits, and wearable devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.